INCI: Brimonidine
Topical alpha-2 adrenergic agonist for rosacea erythema. Constricts superficial vessels and removes redness for 9–12 hours.
Topical application
AProven efficacy. Two or more independent RCTs with instrumental endpoints.
The effect stays symptomatic and does not cure rosacea, only removes redness temporarily. A common issue is rebound erythema after withdrawal or overdose.
Irritation potential
LowAllergen risk
LowPregnancy
CautionBrimonidine (topical) should be used with caution during pregnancy. Consulting a dermatologist or OB-GYN is advisable.
Topical alpha-2 adrenergic agonist for rosacea erythema.
The INCI name is Brimonidine.
Published: · updated: